This document discusses interpreting diagnostic tests for SARS-CoV-2, the virus that causes COVID-19. It describes how reverse transcriptase-polymerase chain reaction (RT-PCR) tests and immunoglobulin M and G (IgM and IgG) enzyme-linked immunosorbent assays (ELISAs) can detect the virus and antibodies over time. RT-PCR tests on nasal swabs are most reliable for detecting the virus within the first 3 weeks of infection. IgM and IgG antibodies start rising in the second week and peak in the third week before IgM declines. Together, PCR and antibody tests can accurately diagnose COVID-19 at different stages of infection.
Detecting neutralization antibodies to covid 19Melvin Alex
A robust serological test to detect neutralizing antibodies to SARS Cov-2 is needed to determine not only the infection rate, herd immunity, and predicted humoral protection, but also vaccine efficacy during clinical trials after large-scale vaccination.
Re-purposing ILRI labs to support national COVID-19 testing in KenyaILRI
Poster prepared by Edward Okoth and Samuel Oyola for the Global Agenda for Sustainable Livestock Africa 1 regional online meeting, 2-3 September 2020. Nairobi, Kenya: ILRI.
Right now the whole world is facing the covid-19 pandemic, and right now diagnosis and prevention of the spread of disease is the best option we have. This presentation includes methods that are currently in use for the identification of SARS-Co-V 2 / Covid-19. other than currently used methods this presentation also includes potential wearable devices that can be used for early detection of Covid-19.
The COVID-19 pandemic is driving the need for rapid development of effective vaccines and therapies. Developing an effective vaccine requires an understanding of the adaptive immune response to SARS-CoV-2. An assay to measure circulating antibodies, specifically neutralizing antibodies (NAbs) that disrupt receptor-binding domain (RBD) and angiotensin-converting enzyme 2 (ACE2) binding to prevent SARS-COV-2 cell entry is an important research tool.
ImmunoRank is a high-throughput surrogate assay that semi-quantitative detects and ranks circulating SARS-CoV-2 neutralizing antibodies of all Ig classes (total antibody) in human plasma or serum. Highly correlated to FRNT or PRNT live virus tests, but is less laborious, takes only 80 minutes to complete, and does not require a BSL3 laboratory.
COIVD 19 Antigen Card is a visual, rapid and sensitive immunoassay for the qualitative detection of COVID-19 (SARS-CoV-2) Antigen in human
nasopharyngeal, nasal swab
specimen.
Detecting neutralization antibodies to covid 19Melvin Alex
A robust serological test to detect neutralizing antibodies to SARS Cov-2 is needed to determine not only the infection rate, herd immunity, and predicted humoral protection, but also vaccine efficacy during clinical trials after large-scale vaccination.
Re-purposing ILRI labs to support national COVID-19 testing in KenyaILRI
Poster prepared by Edward Okoth and Samuel Oyola for the Global Agenda for Sustainable Livestock Africa 1 regional online meeting, 2-3 September 2020. Nairobi, Kenya: ILRI.
Right now the whole world is facing the covid-19 pandemic, and right now diagnosis and prevention of the spread of disease is the best option we have. This presentation includes methods that are currently in use for the identification of SARS-Co-V 2 / Covid-19. other than currently used methods this presentation also includes potential wearable devices that can be used for early detection of Covid-19.
The COVID-19 pandemic is driving the need for rapid development of effective vaccines and therapies. Developing an effective vaccine requires an understanding of the adaptive immune response to SARS-CoV-2. An assay to measure circulating antibodies, specifically neutralizing antibodies (NAbs) that disrupt receptor-binding domain (RBD) and angiotensin-converting enzyme 2 (ACE2) binding to prevent SARS-COV-2 cell entry is an important research tool.
ImmunoRank is a high-throughput surrogate assay that semi-quantitative detects and ranks circulating SARS-CoV-2 neutralizing antibodies of all Ig classes (total antibody) in human plasma or serum. Highly correlated to FRNT or PRNT live virus tests, but is less laborious, takes only 80 minutes to complete, and does not require a BSL3 laboratory.
COIVD 19 Antigen Card is a visual, rapid and sensitive immunoassay for the qualitative detection of COVID-19 (SARS-CoV-2) Antigen in human
nasopharyngeal, nasal swab
specimen.
Coronaviruses belong to the subfamily of Orthocoronavirinae in the family Coronaviridae, in the order Nidovirales. They are enveloped viruses with a positive-sense single-stranded RNA genome and a nucleocapsid of helical symmetry.
Diagnosis of the novel coronavirus disease 2019 (covid 19)Makrani Shaharukh
COVID-19 is a disease caused by a new strain of coronavirus. ‘CO’ stands for corona, ‘VI’ for virus, and ‘D’ for disease. Formerly, this disease was referred to as ‘2019 novel coronavirus’ or ‘2019-nCoV.’The COVID-19 virus is a new virus linked to the same family of viruses as Severe Acute Respiratory Syndrome and some types of common cold. Diagnostic testing is possibly the only efficient way to monitor the spread of the SARS-CoV-2 in time and space.The WHO has appealed for global mass testing.
Rapid diagnostic test for covid 19 may take around 10-20 minutes and are relatively simple to perform and interpret and therefore require limited test operator training. These slides illustrate the general concept of rapid test especially testing IgG and IgM antibodies against SARS-CoV-2 antigen .
Creative Biolabs has established a powerful AntInfect™ Platform for anti-virus biomolecular discovery, covering antibody and antimicrobial peptide (AMP) discovery.
https://www.creative-biolabs.com/antinfect/antibody-peptide-discovery-for-viral-disease.htm
Corona is here to stay and it is predicted that over 70% of population will get the infection (fortunately not all will fall sick or very sick). (Recovery rate of over 74% & Death rate around 2%).
A lot of confusion exists regarding testing for covid and what test to do, when and how to interpret these tests.
Compiled by Dr. Narendra Malhotra
Coronaviruses belong to the subfamily of Orthocoronavirinae in the family Coronaviridae, in the order Nidovirales. They are enveloped viruses with a positive-sense single-stranded RNA genome and a nucleocapsid of helical symmetry.
Diagnosis of the novel coronavirus disease 2019 (covid 19)Makrani Shaharukh
COVID-19 is a disease caused by a new strain of coronavirus. ‘CO’ stands for corona, ‘VI’ for virus, and ‘D’ for disease. Formerly, this disease was referred to as ‘2019 novel coronavirus’ or ‘2019-nCoV.’The COVID-19 virus is a new virus linked to the same family of viruses as Severe Acute Respiratory Syndrome and some types of common cold. Diagnostic testing is possibly the only efficient way to monitor the spread of the SARS-CoV-2 in time and space.The WHO has appealed for global mass testing.
Rapid diagnostic test for covid 19 may take around 10-20 minutes and are relatively simple to perform and interpret and therefore require limited test operator training. These slides illustrate the general concept of rapid test especially testing IgG and IgM antibodies against SARS-CoV-2 antigen .
Creative Biolabs has established a powerful AntInfect™ Platform for anti-virus biomolecular discovery, covering antibody and antimicrobial peptide (AMP) discovery.
https://www.creative-biolabs.com/antinfect/antibody-peptide-discovery-for-viral-disease.htm
Corona is here to stay and it is predicted that over 70% of population will get the infection (fortunately not all will fall sick or very sick). (Recovery rate of over 74% & Death rate around 2%).
A lot of confusion exists regarding testing for covid and what test to do, when and how to interpret these tests.
Compiled by Dr. Narendra Malhotra
Viral load and antibody responses in an asymptomatic/minimally symptomatic SA...komalicarol
Asymptomatic patients with severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), are silent carriers of the disease. We
aimed to characterize their dynamics of disease occurrence, viral
shedding and antibody responses using a cohort of asymptomatic/
minimally symptomatic patients from Sri Lanka during the first
wave of COVID-19.
Viral Load and Antibody Responses in an Asymptomatic/Minimally Symptomatic SA...semualkaira
Asymptomatic patients with severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), are silent carriers of the disease. We
aimed to characterize their dynamics of disease occurrence, viral
shedding and antibody responses using a cohort of asymptomatic/
minimally symptomatic patients from Sri Lanka during the first
wave of COVID-19.
Considerations for Diagnostic COVID-19 Tests in the 4 Medical Testing Centre ...semualkaira
In this study during the coronavirus disease in 2021 (COVID-19)
pandemic, design, development, validation, verification incidence
and implementation of diagnostic tests are reported by many diagnostic tests from May until December 2021 we managed to
establish clinical validation and formal approval. In this article
we summarize the crucial role of diagnostic tests during the first
global wave of COVID-19. The technical and implementation and
diagnostics during a possible resurgence of COVID-19 in future
global waves or regional outbreaks. We continued global improvement in diagnostic test that is essential for more rapid detection of
patients, possibly at the point of care, and for optimized prevention
and treatment
Navigating Challenges: Mental Health, Legislation, and the Prison System in B...Guillermo Rivera
This conference will delve into the intricate intersections between mental health, legal frameworks, and the prison system in Bolivia. It aims to provide a comprehensive overview of the current challenges faced by mental health professionals working within the legislative and correctional landscapes. Topics of discussion will include the prevalence and impact of mental health issues among the incarcerated population, the effectiveness of existing mental health policies and legislation, and potential reforms to enhance the mental health support system within prisons.
CHAPTER 1 SEMESTER V PREVENTIVE-PEDIATRICS.pdfSachin Sharma
This content provides an overview of preventive pediatrics. It defines preventive pediatrics as preventing disease and promoting children's physical, mental, and social well-being to achieve positive health. It discusses antenatal, postnatal, and social preventive pediatrics. It also covers various child health programs like immunization, breastfeeding, ICDS, and the roles of organizations like WHO, UNICEF, and nurses in preventive pediatrics.
CRISPR-Cas9, a revolutionary gene-editing tool, holds immense potential to reshape medicine, agriculture, and our understanding of life. But like any powerful tool, it comes with ethical considerations.
Unveiling CRISPR: This naturally occurring bacterial defense system (crRNA & Cas9 protein) fights viruses. Scientists repurposed it for precise gene editing (correction, deletion, insertion) by targeting specific DNA sequences.
The Promise: CRISPR offers exciting possibilities:
Gene Therapy: Correcting genetic diseases like cystic fibrosis.
Agriculture: Engineering crops resistant to pests and harsh environments.
Research: Studying gene function to unlock new knowledge.
The Peril: Ethical concerns demand attention:
Off-target Effects: Unintended DNA edits can have unforeseen consequences.
Eugenics: Misusing CRISPR for designer babies raises social and ethical questions.
Equity: High costs could limit access to this potentially life-saving technology.
The Path Forward: Responsible development is crucial:
International Collaboration: Clear guidelines are needed for research and human trials.
Public Education: Open discussions ensure informed decisions about CRISPR.
Prioritize Safety and Ethics: Safety and ethical principles must be paramount.
CRISPR offers a powerful tool for a better future, but responsible development and addressing ethical concerns are essential. By prioritizing safety, fostering open dialogue, and ensuring equitable access, we can harness CRISPR's power for the benefit of all. (2998 characters)
Health Education on prevention of hypertensionRadhika kulvi
Hypertension is a chronic condition of concern due to its role in the causation of coronary heart diseases. Hypertension is a worldwide epidemic and important risk factor for coronary artery disease, stroke and renal diseases. Blood pressure is the force exerted by the blood against the walls of the blood vessels and is sufficient to maintain tissue perfusion during activity and rest. Hypertension is sustained elevation of BP. In adults, HTN exists when systolic blood pressure is equal to or greater than 140mmHg or diastolic BP is equal to or greater than 90mmHg. The
Deep Leg Vein Thrombosis (DVT): Meaning, Causes, Symptoms, Treatment, and Mor...The Lifesciences Magazine
Deep Leg Vein Thrombosis occurs when a blood clot forms in one or more of the deep veins in the legs. These clots can impede blood flow, leading to severe complications.
Empowering ACOs: Leveraging Quality Management Tools for MIPS and BeyondHealth Catalyst
Join us as we delve into the crucial realm of quality reporting for MSSP (Medicare Shared Savings Program) Accountable Care Organizations (ACOs).
In this session, we will explore how a robust quality management solution can empower your organization to meet regulatory requirements and improve processes for MIPS reporting and internal quality programs. Learn how our MeasureAble application enables compliance and fosters continuous improvement.
Medical Technology Tackles New Health Care Demand - Research Report - March 2...pchutichetpong
M Capital Group (“MCG”) predicts that with, against, despite, and even without the global pandemic, the medical technology (MedTech) industry shows signs of continuous healthy growth, driven by smaller, faster, and cheaper devices, growing demand for home-based applications, technological innovation, strategic acquisitions, investments, and SPAC listings. MCG predicts that this should reflects itself in annual growth of over 6%, well beyond 2028.
According to Chris Mouchabhani, Managing Partner at M Capital Group, “Despite all economic scenarios that one may consider, beyond overall economic shocks, medical technology should remain one of the most promising and robust sectors over the short to medium term and well beyond 2028.”
There is a movement towards home-based care for the elderly, next generation scanning and MRI devices, wearable technology, artificial intelligence incorporation, and online connectivity. Experts also see a focus on predictive, preventive, personalized, participatory, and precision medicine, with rising levels of integration of home care and technological innovation.
The average cost of treatment has been rising across the board, creating additional financial burdens to governments, healthcare providers and insurance companies. According to MCG, cost-per-inpatient-stay in the United States alone rose on average annually by over 13% between 2014 to 2021, leading MedTech to focus research efforts on optimized medical equipment at lower price points, whilst emphasizing portability and ease of use. Namely, 46% of the 1,008 medical technology companies in the 2021 MedTech Innovator (“MTI”) database are focusing on prevention, wellness, detection, or diagnosis, signaling a clear push for preventive care to also tackle costs.
In addition, there has also been a lasting impact on consumer and medical demand for home care, supported by the pandemic. Lockdowns, closure of care facilities, and healthcare systems subjected to capacity pressure, accelerated demand away from traditional inpatient care. Now, outpatient care solutions are driving industry production, with nearly 70% of recent diagnostics start-up companies producing products in areas such as ambulatory clinics, at-home care, and self-administered diagnostics.
India Clinical Trials Market: Industry Size and Growth Trends [2030] Analyzed...Kumar Satyam
According to TechSci Research report, "India Clinical Trials Market- By Region, Competition, Forecast & Opportunities, 2030F," the India Clinical Trials Market was valued at USD 2.05 billion in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 8.64% through 2030. The market is driven by a variety of factors, making India an attractive destination for pharmaceutical companies and researchers. India's vast and diverse patient population, cost-effective operational environment, and a large pool of skilled medical professionals contribute significantly to the market's growth. Additionally, increasing government support in streamlining regulations and the growing prevalence of lifestyle diseases further propel the clinical trials market.
Growing Prevalence of Lifestyle Diseases
The rising incidence of lifestyle diseases such as diabetes, cardiovascular diseases, and cancer is a major trend driving the clinical trials market in India. These conditions necessitate the development and testing of new treatment methods, creating a robust demand for clinical trials. The increasing burden of these diseases highlights the need for innovative therapies and underscores the importance of India as a key player in global clinical research.
One of the most developed cities of India, the city of Chennai is the capital of Tamilnadu and many people from different parts of India come here to earn their bread and butter. Being a metropolitan, the city is filled with towering building and beaches but the sad part as with almost every Indian city